Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.
The morphometric analysis of the size of adenomatous prolactin cells shows that bromocriptine-induced cell shrinkage halts if treatment with the drug is discontinued for more than 2 days. Different cell components (nucleus, cytoplasm, nucleolus) do not react to treatment to the same extent.
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001971:Bromocriptine / Q000627:therapeutic use*; D002467:Cell Nucleus / Q000473:pathology; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011388:Prolactin / Q000378:metabolism*
D001971:Bromocriptine; D011388:Prolactin